Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06046729 · ClinicalTrials.gov registry record · Phase 2

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
352
Enrollment target
20
Study locations

NCT06046729 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 352 participants, below the 591-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06046729, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
352 participants
Enrollment target
20
Study locations

Study Summary

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG Placebo
  • DRUG Eltrekibart

Study Locations (20)

Florida

  • Direct Helpers Research Center - Hialeah
  • University of Miami - Miami
  • Skin Research of South Florida - Miami
  • ForCare Clinical Research - Tampa
  • Alliance Clinical Research of Tampa - Tampa
  • Olympian Clinical Research - Tampa

California

  • First OC Dermatology Research Inc - Fountain Valley
  • Center For Dermatology Clinical Research, Inc. - Fremont
  • Dermatology Research Associates - Los Angeles
  • Dermatology Institute and Skin Care Center - Santa Monica

Arizona

  • Medical Dermatology Specialists - Phoenix
  • Saguaro Dermatology Associates, LLC - Probity - PPDS - Phoenix

Arkansas

  • Arkansas Research Trials, LLC - North Little Rock
  • Northwest Arkansas Clinical Trials Center - Rogers

Kentucky

  • Equity Medical - Bowling Green - Bowling Green
  • Derm Research LLC - Louisville

Connecticut

  • University of Connecticut - Farmington

Georgia

  • Advanced Medical Research, PC - Sandy Springs

Illinois

  • NorthShore Medical Group Dermatology - Skokie - Skokie

Trial Details

FieldValue
Enrollment Target 352 participants
Start Date 2023-10-23
Est. Completion 2026-08
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06046729

The ClinicalTrials.gov registry entry for NCT06046729 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 591-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (40% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06046729 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06046729 about?

NCT06046729 is a clinical study titled "A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

What is the current status of trial NCT06046729?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 352 participants. The study started on 2023-10-23. Estimated completion is 2026-08.

What conditions does trial NCT06046729 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT06046729?

The interventions under investigation include: Placebo (DRUG), Eltrekibart (DRUG).

Who is sponsoring clinical trial NCT06046729?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06046729 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.